摘要
目的:探讨沙格列汀联合阿卡波糖治疗新发2型糖尿病(type 2 diabetes mellitus,T2DM)的临床效果。方法:选取2018年1月-2019年10月笔者所在医院诊治的T2DM者100例,按随机数字法将患者分为观察组和对照组,每组50例。对照组给予阿卡波糖治疗,观察组给予沙格列汀联合阿卡波糖治疗,对比两组治疗前后体质指数(BMI)、糖化血红蛋白(HbA1c)、餐后2 h血糖、胰岛素抵抗指数、空腹血糖各指标及餐后2 h胰岛素、HOMA-β、空腹胰岛素及不良反应发生率。结果:治疗前两组BMI、HbA1c比较差异无统计学意义(P>0.05),治疗后两组HbA1c均低于治疗前,差异均有统计学意义(P<0.05);两组BMI与治疗前比较差异无统计学意义(P>0.05),治疗后两组BMI、HbA1c比较差异无统计学意义(P>0.05)。观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。治疗后观察组餐后2 h血糖、胰岛素抵抗、空腹血糖均低于对照组,差异均有统计学意义(P<0.05)。治疗后观察组餐后2 h胰岛素、HOMA-β、空腹胰岛素均高于对照组,差异均有统计学意义(P<0.05)。结论:沙格列汀联合阿卡波糖治疗新发2型糖尿病可明显改善患者HbA1c,降低患者血糖指标,升高患者胰岛素指标,且不良反应发生率低,临床疗效显著。
Objective:To explore the clinical efficacy of Saxagliptin combined with Acarbose in treatment of newly diagnosed type 2 diabetes mellitus(T2DM).Method:A total of 100 T2DM patients treated in our hospital from January 2018 to October 2019 were selected and divided into the observation group and the control group according to random number method,with 50 cases in each group.Patients in the control group were treated with Carbohydrase,while patients in the observation group were treated with Saxagliptin combined with Acarbose.The values of body mass index(BMI)and glycosylated hemoglobin(HbA1c)were compared between the two groups before and after treatment.Incidence of adverse reactions in two groups.The indexes of blood glucose,insulin resistance,fasting blood glucose,insulin,HOMA-βand fasting insulin at 2 hours after meal were compared between the two groups.Result:Before treatment,there were no significant differences in BMI and HbA1c between the two groups(P>0.05).After treatment,HbA1c in the two groups was lower than before treatment,and the difference was statistically significant(P<0.05).After treatment,there were no significant differences in BMI and HbA1c between the two groups(P>0.05).The incidence of adverse reactions in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).After treatment,2 h postprandial insulin,HOMA-β,fasting insulin in the observation group were higher than those of the control group(P<0.05).Conclusion:Saxagliptin combined with Acarbose can significantly improve HbA1c value,decrease blood glucose index and increase insulin index in patients with newly diagnosed type 2 diabetes mellitus(T2DM),with low incidence of adverse reactions and significant clinical effect.
作者
刘卫
喻红兵
LIU Wei;YU Hongbing(Huangshi Aikang Hospital,Huangshi 435000,China;不详)
出处
《中外医学研究》
2021年第14期39-41,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
沙格列汀
阿卡波糖
新发2型糖尿病
疗效
Saxagliptin
Acarbose
New-onset type 2 diabetes mellitus
Curative effect
